Condition
Central Nervous System Embryonal Neoplasm
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT00983398Phase 1UnknownPrimary
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
NCT00010114CompletedPrimary
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children
Showing all 2 trials